Christopher Ong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Christopher Ong has a total of 126 co-authors. Here are the top co-authors by number of shared publications:
- Martin Gleave
University of British Columbia 11 Department of Urologic Sciences Vancouver, Canada
26 shared publications - Yuzhuo Wang
Vancouver Prostate Centre, Department of Urological Sciences, University of British Columbia, Vancouver, BC V6H 3Z6, Canada
22 shared publications - Dong Lin
Department of Experimental Therapeutics, BC Cancer, Vancouver, Canada
19 shared publications - Mads Daugaard
Vancouver Prostate Centre, Vancouver, Canada
19 shared publications - Adam Classen
Department of Experimental Therapeutics, BC Cancer, Vancouver, Canada
18 shared publications - Angela Trinh
GenomeMe Lab Inc., Richmond, Canada
18 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Exploring B7-H4’s Role in Prostate Cancer Dormancy after Androgen Deprivation Therapy: Extracellular Matrix Interactions and Therapeutic Opportunities
Table S2. Biological characteristics and genetic background of PDX lines
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Exploring B7-H4’s Role in Prostate Cancer Dormancy after Androgen Deprivation Therapy: Extracellular Matrix Interactions and Therapeutic Opportunities
Table S2. Biological characteristics and genetic background of PDX lines
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Exploring B7-H4’s Role in Prostate Cancer Dormancy after Androgen Deprivation Therapy: Extracellular Matrix Interactions and Therapeutic Opportunities
Fig. S4. Stroma accumulation and ECM remodeling coincided with VTCN1 upregulation in response to reduced AR activity in post-NHT patients with prostate cancer.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Exploring B7-H4’s Role in Prostate Cancer Dormancy after Androgen Deprivation Therapy: Extracellular Matrix Interactions and Therapeutic Opportunities
Fig. S4. Stroma accumulation and ECM remodeling coincided with VTCN1 upregulation in response to reduced AR activity in post-NHT patients with prostate cancer.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Exploring B7-H4’s Role in Prostate Cancer Dormancy after Androgen Deprivation Therapy: Extracellular Matrix Interactions and Therapeutic Opportunities
Fig. S3. Lack of correlation between B7-H4 expression and immune activity in post-NHT prostate cancer.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Exploring B7-H4’s Role in Prostate Cancer Dormancy after Androgen Deprivation Therapy: Extracellular Matrix Interactions and Therapeutic Opportunities
Fig. S3. Lack of correlation between B7-H4 expression and immune activity in post-NHT prostate cancer.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Exploring B7-H4’s Role in Prostate Cancer Dormancy after Androgen Deprivation Therapy: Extracellular Matrix Interactions and Therapeutic Opportunities
Fig. S1. scRNA-seq analysis of human prostate cancer cells from the LTL331 PDX model showing VTCN1 expression across all 17 clusters.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Exploring B7-H4’s Role in Prostate Cancer Dormancy after Androgen Deprivation Therapy: Extracellular Matrix Interactions and Therapeutic Opportunities
Fig. S1. scRNA-seq analysis of human prostate cancer cells from the LTL331 PDX model showing VTCN1 expression across all 17 clusters.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Exploring B7-H4’s Role in Prostate Cancer Dormancy after Androgen Deprivation Therapy: Extracellular Matrix Interactions and Therapeutic Opportunities
Table S1. Baseline patient characteristics of TMA samples
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Exploring B7-H4’s Role in Prostate Cancer Dormancy after Androgen Deprivation Therapy: Extracellular Matrix Interactions and Therapeutic Opportunities
Table S1. Baseline patient characteristics of TMA samples
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Exploring B7-H4’s Role in Prostate Cancer Dormancy after Androgen Deprivation Therapy: Extracellular Matrix Interactions and Therapeutic Opportunities
Fig. S2. VTCN1 (mouse B7-H4) expression enriched in post-castration prostate tissue in a normal mouse prostate tissue castration model.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Exploring B7-H4’s Role in Prostate Cancer Dormancy after Androgen Deprivation Therapy: Extracellular Matrix Interactions and Therapeutic Opportunities
Fig. S2. VTCN1 (mouse B7-H4) expression enriched in post-castration prostate tissue in a normal mouse prostate tissue castration model.
- Open Access
PARP Inhibition in Prostate Cancer: Current Status, Resistance Mechanisms, and Clinical Challenges
Poly(ADP-ribose) polymerase inhibitors (PARPi) have reshaped therapy for advanced prostate cancer, yet durable benefit remains concentrated in BRCA1/2-altered tumors, especially BRCA2, and most responders eventually relapse. Here, we frame PARPi response and resistance through a unifying model in which DNA damage response (DDR) rewiring (e.g., homologous recombination repair (HRR) restoration, fork protection, checkpoint tolerance, and altered drug handling) converges with treatment-induced dormancy and quiescent therapy-tolerant residual states that sustain minimal residual disease (MRD) under androgen receptor pathway inhibition (ARPI) and PARP blockade. We synthesize clinical and translational evidence for PARPi monotherapy and PARPi-based combinations across disease states. In first-line metastatic castration-resistant prostate cancer (mCRPC), PARPi plus ARPI consistently prolongs radiographic progression-free survival, with the greatest benefit in HRR-altered tumors, and emerging overall-survival signals in selected subgroups. In later-line settings, monotherapy activity is most robust in BRCA2-mutated disease, whereas non-BRCA HRR alterations show heterogeneous and often modest responses, underscoring the need for biomarkers beyond gene panels. We also discuss combination strategies with DDR-targeting agents, radioligand therapies, and immunotherapy, and summarize ongoing phase III programs in metastatic castration-sensitive prostate cancer (mCSPC). Finally, we outline practical considerations for biomarker-informed patient selection, monitoring, sequencing, and toxicity management, with particular emphasis on intercepting MRD and resistance evolution.
Open AccessPARP Inhibition in Prostate Cancer: Current Status, Resistance Mechanisms, and Clinical Challenges
Poly(ADP-ribose) polymerase inhibitors (PARPi) have reshaped therapy for advanced prostate cancer, yet durable benefit remains concentrated in BRCA1/2-altered tumors, especially BRCA2, and most responders eventually relapse. Here, we frame PARPi response and resistance through a unifying model in which DNA damage response (DDR) rewiring (e.g., homologous recombination repair (HRR) restoration, fork protection, checkpoint tolerance, and altered drug handling) converges with treatment-induced dormancy and quiescent therapy-tolerant residual states that sustain minimal residual disease (MRD) under androgen receptor pathway inhibition (ARPI) and PARP blockade. We synthesize clinical and translational evidence for PARPi monotherapy and PARPi-based combinations across disease states. In first-line metastatic castration-resistant prostate cancer (mCRPC), PARPi plus ARPI consistently prolongs radiographic progression-free survival, with the greatest benefit in HRR-altered tumors, and emerging overall-survival signals in selected subgroups. In later-line settings, monotherapy activity is most robust in BRCA2-mutated disease, whereas non-BRCA HRR alterations show heterogeneous and often modest responses, underscoring the need for biomarkers beyond gene panels. We also discuss combination strategies with DDR-targeting agents, radioligand therapies, and immunotherapy, and summarize ongoing phase III programs in metastatic castration-sensitive prostate cancer (mCSPC). Finally, we outline practical considerations for biomarker-informed patient selection, monitoring, sequencing, and toxicity management, with particular emphasis on intercepting MRD and resistance evolution.
- Open Access
- 10 June 2025
- Published by Elsevier in Cell Genomics
- Vol. 5 (8) , 100916
CXCR4-LASP1-G9a-SNAIL axis drives NEPC transdifferentiation via induction of EMT and downregulation of REST
- 10 June 2025
- Published by Elsevier in Cell Genomics
- Vol. 5 (8) , 100916
Open AccessCXCR4-LASP1-G9a-SNAIL axis drives NEPC transdifferentiation via induction of EMT and downregulation of REST